Navigation Links
New possibilities for flu antiviral and vaccine research emerge from 'Spanish flu' virus

es that made the 1918 virus so exceptionally deadly. We wanted to identify the specific genes responsible for its virulence, with the hope of designing antivirals or other interventions that would work against virulent pandemic or epidemic influenza viruses," said Tumpey.

"Science is publishing this study because it provides information necessary for developing drugs and vaccines that could help prevent another global flu pandemic. We carefully considered the implications of publishing this research and concluded that the knowledge we're gaining to potentially protect public health far outweighs the risk of working with this virus," said Donald Kennedy, editor-in-chief of Science.

"We were comforted to learn that this also was the conclusion of Dr. Anthony Fauci of the U.S. National Institute of Allergy and Infectious Diseases, Dr. Julie Gerberding of the Centers for Disease Control and Prevention, and Dr. Amy Patterson of the Office of Biotechnology Activities within the Office of Science Policy at the U.S. National Institutes of Health. Dr. Patterson is the spokesperson for the National Science Advisory Board for Biodefense (NSABB), which provides guidance and advice on the implications for dual use research and publication," Kennedy said.

To make the virus, the researchers used an approach called "reverse genetics," which involves transferring gene sequences of viral RNA into bacteria and then inserting combinations of the genes -- often after manipulating them -- into cell lines, where they combine to form a virus.

For the Science study, Jeffery Taubenberger of the Armed Forces Institute of Pathology provided the coding sequences for the eight Spanish flu genes to Christopher Basler, Peter Palese, Adolfo Garcíˇ­Sastre and their colleagues at the Mount Sinai School of Medicine. They spliced these sequences together with noncoding DNA from a closely related virus, since this portion of the genome wasn't available for the Spanish flu
'"/>

Source:American Association for the Advancement of Science


Page: 1 2 3

Related biology news :

1. New possibilities to fight pests with biological means
2. Three-dimensional, miniature endoscope opens new diagnostic possibilities
3. Heart failure: Intervention possibilities from imaging programmed cell loss
4. The quest for an effective HIV vaccine presents new possibilities, challenges
5. Novel antiviral technology inhibits RSV infection in mice
6. Biota makes major antiviral discovery
7. The reason why antiviral therapy cant annihilate HIV infection, and what to do about it
8. Bird flu -- Call for antiviral drugs to be shared
9. Research advances quest for HIV-1 vaccine
10. A much-needed shot in the arm for HIV vaccine development
11. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
Post Your Comments:
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... University previously developed ion transistors for transport of both ... has now succeeded in combining both transistor types into ... electronics. An advantage of chemical circuits is ... various functions. This means that we now have new ...
... University in Sweden reveals the value of carrying two layers ... way their protective forewings actually function. These wings do not ... from the ground albeit at a cost. The ... the insect,s flying wings and body. The function of the ...
... As gardeners get busy filling tubs and borders with ... Bristol have discovered more about what makes flowers attractive to ... Society,s journal Functional Ecology , their research reveals that ... helping bees grip flowers especially when the wind gets ...
Cached Biology News:Flapping protective wings increase lift 2Blowing in the wind: How hidden flower features are crucial for bees 2
(Date:5/22/2015)... 22, 2015 Baylor Research Institute (BRI) ... Genomics Research Institute (TGen) in Phoenix, AZ ... accelerating early detection and treatments for patients with a broad ... will lead to new clinical trials and access to technology ... gap from bench to bedside across Baylor Scott ...
(Date:5/21/2015)... -- Prima Biomed Ltd. (NASDAQ: PBMD ) a globally ... leader in the development of immunotherapeutic products for the ... data from the Phase II CAN-003 ovarian cancer clinical ... meaningful improvement in Overall Survival ("OS") over standard of ... the group of second remission patients (n=20), the median ...
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains ... therapeutic imaging within a body lumen (open space). ... a low cost, single-use disposable illumination and camera module ... 18, 2013 and the patent approval was received on ... to customize the lighting and magnification of the endoscope ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, Endetec, ... agreement with VWR to distribute TECTA™ B16, an ... 160 years of experience, VWR, a leading global ... production facilities, has cultivated a value proposition delivering ... enable science. Endetec’s TECTA™ B16, combines proven ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Correction Continues after Big Move - BrokerBank Securities, Inc. 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... on its flagship,suite of medication and infusion management ... and an industry-first Performance,Analytics Service that provides hospitals ... , The ... features that can help hospitals increase the security ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that ... in a panel,discussion at the 2008 RBC Capital Marketing Healthcare ... Rheumatology", will take,place on Wednesday, December 10, 2008 at 10:00 ... City. , To access ...
... - Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority ... patients with genotypes 2 and 3 chronic hepatitis C - ... receiving 900-mcg Albuferon had comparable rates of serious adverse events, ... peginterferon alfa-2a - , , ...
Cached Biology Technology:Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 2Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 4Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 5Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 6Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 7Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 8Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 9
... and non-reduced forms. It does not react with ... Factor XIII is a Beta-globulin found in plasma ... is the catalytic subunit and is a dimmer ... plasma as an Alpha2Beta2 heterodimer (M.W. 320kDa); whereas ...
... DNAscope V is a fully integrated ... and image processing that deliver excellent quality ... a high quality microarray scanner that is ... for optimal background rejection and spatial resolution. ...
... Anti-MAPKAPK-2, Phospho-Specific(Thr 222 ) ... NaCl, 10 mM sodium HEPES, ... pH 7.5. Recognizes the ~47 ... 2 (MAPKAPK-2) protein phosphorylated at ...
Anti-Src-Like Adaptor Protein-2 AVOID FREEZE/THAW CYCLES. Recognizes the ~25 and ~28 kDa forms SLAP-2....
Biology Products: